Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03QMY
|
|||
| Former ID |
DNCL002722
|
|||
| Drug Name |
IDM-2101
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 2 | [1] | |
| Company |
Biotech Synergy
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Carcinoembryonic antigen CEA (CD66e) | Target Info | . | [1] |
| Melanoma-associated antigen 3 (MAGEA3) | Target Info | . | [1] | |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep 20;26(27):4418-25. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.